SeQure DX™ is setting the standard for precision analytics in gene editing, delivering best-in-class off-target risk assessment services to advance safer, more effective cell and gene therapies.
We provide a comprehensive suite of trusted assays—such as ONE-seq®, GUIDE-seq™, DEUX-seq™, Amplicon-seq™, Guide Profiler™, Guide Select™, and SAFER Detection™—that enable developers to detect, nominate, and confirm gene editing outcomes with high sensitivity and regulatory alignment.
In January 2025, SeQure DX™ was acquired by MaxCyte, Inc., a leading cell engineering company, to form the core of MaxCyte’s Cell & Gene Therapy (CGT) Services business. Together, we provide an integrated solution that combines world-class cell engineering and comprehensive gene editing risk assessment services, helping therapeutic developers mitigate risk in their programs, accelerate timelines, and enable regulatory confidence from discovery through clinical stage and beyond.
Company Details
- Employees
- 17
- Founded
- -
- Address
- 1440 Main St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://maxcyte.com/sequre-dx
- HQ
- Waltham, MA
Sequre Dx Questions
Sequre Dx's website is http://maxcyte.com/sequre-dx
Sequre Dx's LinkedIn profile is https://www.linkedin.com/company/sequre-dx
Sequre Dx has
17 employees.
View email and phone details for 17
employees at Sequre Dx.
Sequre Dx's industry is
Biotechnology Research
Sequre Dx's top competitors are
Bluejay Therapeutics,
Maxcyte, Inc.,
Scout Bio,
Kytopen,
Foundation Medicine,
Foresight Diagnostics,
Eli Lilly And Company,
Verve Therapeutics,
Bostongene,
Biolinq.
Sequre Dx's categories are Biotechnology Research
Sequre Dx's founding year is 2021
